EJNMMI Research

Table 1 The RPPA markers that showed significant modulations after 1 day of the RO4987655 treatment

From: Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [¹⁸F] FDG-PET imaging combined with proteomic approaches

Analyte	Pvalue	Pathway
	Down-regulated
ERK1/2-P-Thr201/Tyr204	<0.001	MAPK
PKC alpha/beta II-P-Thr638/641	<0.001	cAMP/metabolism
MKK4-P-Ser257/Thr261	<0.001	MAPK
mTOR-P-Ser2448	0.005	mTOR
EGFR-P-Tyr1068	0.0039	RTK
PKA C-alpha/beta/gamma-P-Thr197	0.0049	c/AMP/metabolism
GSK3 beta-P-Ser9	0.0267	Wnt/metabolism
MEK1/2-P-Ser217/221	0.00267	MAPK
	Up-regulated
IGF-receptor	0.0034	Insulin
4E-BP1	0.0062	Metabolism
Cyclin D	0.0168	Cell cycle control
P53	0.0221	Cell cycle control
Akt-P-ser473	0.0991	Akt/metabolism
MEK2	0.6743	MAPK
C-met	0.8373	RTK

Back to article page